78 research outputs found
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment
Background: High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010. Methods: We used data for exposure to risk factors by country, age group, and sex from pooled analyses of population-based health surveys. We obtained relative risks for the effects of risk factors on cause-specific mortality from meta-analyses of large prospective studies. We calculated the population attributable fractions for each risk factor alone, and for the combination of all risk factors, accounting for multicausality and for mediation of the effects of BMI by the other three risks. We calculated attributable deaths by multiplying the cause-specific population attributable fractions by the number of disease-specific deaths. We obtained cause-specific mortality from the Global Burden of Diseases, Injuries, and Risk Factors 2010 Study. We propagated the uncertainties of all the inputs to the final estimates. Findings: In 2010, high blood pressure was the leading risk factor for deaths due to cardiovascular diseases, chronic kidney disease, and diabetes in every region, causing more than 40% of worldwide deaths from these diseases; high BMI and glucose were each responsible for about 15% of deaths, and high cholesterol for more than 10%. After accounting for multicausality, 63% (10·8 million deaths, 95% CI 10·1-11·5) of deaths from these diseases in 2010 were attributable to the combined effect of these four metabolic risk factors, compared with 67% (7·1 million deaths, 6·6-7·6) in 1980. The mortality burden of high BMI and glucose nearly doubled from 1980 to 2010. At the country level, age-standardised death rates from these diseases attributable to the combined effects of these four risk factors surpassed 925 deaths per 100 000 for men in Belarus, Kazakhstan, and Mongolia, but were less than 130 deaths per 100 000 for women and less than 200 for men in some high-income countries including Australia, Canada, France, Japan, the Netherlands, Singapore, South Korea, and Spain. Interpretation: The salient features of the cardiometabolic disease and risk factor epidemic at the beginning of the 21st century are high blood pressure and an increasing effect of obesity and diabetes. The mortality burden of cardiometabolic risk factors has shifted from high-income to low-income and middle-income countries. Lowering cardiometabolic risks through dietary, behavioural, and pharmacological interventions should be a part of the global response to non-communicable diseases. Funding: UK Medical Research Council, US National Institutes of Health. © 2014 Elsevier Ltd
Study of the Kp-interactions at 250-300 GeV/c by means of a rapid cycling bubble chamber set-up
Blood Pressure Response Under Chronic Antihypertensive Drug Therapy The Role of Aortic Stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) Study
Objectives We sought to evaluate the role of arterial stiffness on blood
pressure (BP) response to drug treatment.
Background Increased arterial stiffness (pulse wave velocity [PWV]) is
associated with increased systolic blood pressure (SBP).
Antihypertensive drug therapy achieves better control of diastolic blood
pressure (DBP) than SBP does, implying that increased PWV might be a
predictor of the SBP response to treatment.
Methods The REASON (Preterax in Regression of Arterial Stiffness in a
Controlled Double-Blind) study is a randomized, double-blind trial
comparing atenolol versus perindopril/indapamide; 375 patients with
hypertension, with BP and PWV measurements at baseline and after 12
months of treatment, were divided into 3 tertiles according to baseline
PWV and included in a post-hoc analysis.
Results After 12 months of treatment, BP differed significantly between
PWV tertiles (the third having the lowest response, p < 0.05). Factors
related to smaller BP decline were low baseline BP, high baseline PWV,
need for a double dose of treatment, use of atenolol (only for SBP
response), and age (only for DBP). Although DBP control did not differ
in the PWV tertiles, SBP control was significantly associated with PWV
level (p = 0.001) as well as with the use of perindopril/indapamide (p <
0.001). The predictive value of PWV on BP response was independent of
age, sex, mean BP, and cardiovascular risk factors.
Conclusions Baseline PWV is a significant predictor of BP response to
antihypertensive treatment, independent from age, the need for
increasing drug dosage, and the presence of cardiovascular risk factors.
Achievement of SBP control appears to be influenced by aortic stiffness
as well as by angiotensin-converting enzyme inhibition. (J Am Coll
Cardiol 2009;53:445-51) (C) 2009 by the American College of Cardiology
Foundatio
Cost estimation of hypertension management based on home blood pressure monitoring alone or combined office and ambulatory blood pressure measurements
Non-invasive 24hour ambulatory monitoring of aortic wave reflection and arterial stiffness by a novel oscillometric device: The first feasibility and reproducibility study
- …